Biodesix (BDSX) Accumulated Expenses (2019 - 2026)

Biodesix (BDSX) has 8 years of Accumulated Expenses data on file, last reported at $805000.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 4.62% year-over-year to $805000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $805000.0 (down 4.62% YoY) and the FY2025 annual result came in at $7.8 million, down 22.16% from the prior year.
• Accumulated Expenses retreated to $805000.0 in Q1 2026, from $7.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.1 million in Q4 2024 to a low of $805000.0 in Q1 2026.
• A 5-year average of $4.2 million and a median of $3.9 million in 2023 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 638.94% in 2025, down 89.31% in 2025.
• Tracing BDSX's Accumulated Expenses over 5 years: stood at $4.7 million in 2022, then decreased by 17.47% to $3.9 million in 2023, then jumped by 161.06% to $10.1 million in 2024, then decreased by 22.16% to $7.8 million in 2025, then sank by 89.72% to $805000.0 in 2026.
• The last three Accumulated Expenses figures came in at $805000.0 (Q1 2026), $7.8 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.